Beyond the Prototype: Delhi High Court Remands Harvard Patent Case Over Procedural Oversight

In a significant ruling for patent practice in India, the Delhi High Court has set aside an order by the Controller General of Patents, Designs, and Trademarks that refused a patent application filed by the President and Fellows of Harvard College. The conflict centered on "SC-β cells"—stem cell-derived pancreatic beta cells—and whether the patent application fell within the "non-patentable" criteria under Section 3(j) of the Patents Act, 1970.

The High Court’s intervention, presided over by Justice Tejas Karia, did not delve into the underlying biological merits of the scientific invention. Instead, it focused on a procedural failure: the Patent Controller’s oversight in refusing the application without reviewing the "amended claims" submitted by the university following the hearing.

The Disputed Application

Harvard’s application specifically concerned “SC-β cells and compositions and methods for generating the same.” The appellant sought protection for non-native pancreatic beta cells, engineered through a proprietary differentiation process to manage glucose levels effectively.

During the examination process, the Patent Controller initially objected to the claims on multiple grounds, including lack of definitiveness (Sections 10(4) and 10(5)) and non-patentability (Sections 3(j) and 3(e)). While the university submitted a comprehensive reply and amended claims, the final order of refusal issued on August 25, 2022, was based exclusively on the original claims, ignoring the supplemental amendments that sought to refine the legal scope of the protection.

A Procedural Correction

The appellant argued that the failure to review the amended claims prevented a fair assessment of the technical merits. The High Court agreed, finding that the refusal constituted a “glaring error.”

In his analysis, Justice Karia cited precedents like Jitendra Kohli v. The Controller of Patents , emphasizing that ignoring amended submissions is a procedural breakdown. The court noted that because the amended claims fundamentally shifted the focus from broad composition claims to specific cell-type descriptions, the basis of the original rejection was no longer accurate or comprehensive.

Key Observations

Highlighting the gravity of overlooking updated pleadings, the Court observed:

> "It is clear from the amended claims that they are not composition claims as evident from the comparison of original claim no. 1 and amended claim no. 1."

The Court further underscored the importance of procedural duty upon the authority:

> "As the Impugned Order has not considered the amended claims placed on record, it is clear that a fresh order shall be passed after duly considering the amended claims on all counts including novelty, inventive step and patentability."

> "Consequently, amended claims that significantly alter the original claims transitioning from a composition to a non-native pancreatic β cell must be duly considered by the learned Controller independently..."

Implications for Patent Applicants

The decision serves as a reminder to patent authorities that administrative efficiency cannot come at the cost of thoroughness. By remanding the case, the Delhi High Court has mandated that the Controller General undertake a fresh examination of the application, now considering the refined, amended claims.

The Controller has been directed to arrive at a reasoned decision within six months. Crucially, the court ordered that a different officer preside over the new examination to ensure impartiality and prevent any “pre-determination” based on the earlier, flawed rejection. For innovators and global research institutions alike, the ruling clarifies that the process of refining claims is a core right that cannot be bypassed, ensuring that the legal gatekeepers of innovation engage with the latest version of an invention.